OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.
Saved in:
| Title: | OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models. |
|---|---|
| Authors: | Berenguer-Daizé C; Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, 13385, France., Astorgues-Xerri L; Oncology Therapeutic Development, 100 Rue Martre, Clichy, 92110, France., Odore E; Oncology Therapeutic Development, 100 Rue Martre, Clichy, 92110, France.; Department of Radio-Pharmacology, Institut Curie, René Huguenin Hospital, 35 Rue Daily, Saint-Cloud, 92210, France., Cayol M; Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, 13385, France., Cvitkovic E; Oncology Therapeutic Development, 100 Rue Martre, Clichy, 92110, France.; Oncoethix SA (Now Oncoethix GmbH, a Wholly Owned Subsidiary of Merck Sharp and Dohme Corp.), Weystrasse 20, Lucerne, 6000, Switzerland., Noel K; Oncoethix SA (Now Oncoethix GmbH, a Wholly Owned Subsidiary of Merck Sharp and Dohme Corp.), Weystrasse 20, Lucerne, 6000, Switzerland., Bekradda M; Oncology Therapeutic Development, 100 Rue Martre, Clichy, 92110, France., MacKenzie S; Oncology Therapeutic Development, 100 Rue Martre, Clichy, 92110, France., Rezai K; Department of Radio-Pharmacology, Institut Curie, René Huguenin Hospital, 35 Rue Daily, Saint-Cloud, 92210, France., Lokiec F; Department of Radio-Pharmacology, Institut Curie, René Huguenin Hospital, 35 Rue Daily, Saint-Cloud, 92210, France., Riveiro ME; Oncology Therapeutic Development, 100 Rue Martre, Clichy, 92110, France., Ouafik L; Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, 13385, France. |
| Source: | International journal of cancer [Int J Cancer] 2016 Nov 01; Vol. 139 (9), pp. 2047-55. Date of Electronic Publication: 2016 Jul 30. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Wiley-Liss Country of Publication: United States NLM ID: 0042124 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0215 (Electronic) Linking ISSN: 00207136 NLM ISO Abbreviation: Int J Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 27388964 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Berenguer-Daizé+C%22">Berenguer-Daizé C</searchLink>; Aix-Marseille Université, Inserm, CRO2 UMR&#95;S 911, Marseille, 13385, France.<br /><searchLink fieldCode="AU" term="%22Astorgues-Xerri+L%22">Astorgues-Xerri L</searchLink>; Oncology Therapeutic Development, 100 Rue Martre, Clichy, 92110, France.<br /><searchLink fieldCode="AU" term="%22Odore+E%22">Odore E</searchLink>; Oncology Therapeutic Development, 100 Rue Martre, Clichy, 92110, France.; Department of Radio-Pharmacology, Institut Curie, René Huguenin Hospital, 35 Rue Daily, Saint-Cloud, 92210, France.<br /><searchLink fieldCode="AU" term="%22Cayol+M%22">Cayol M</searchLink>; Aix-Marseille Université, Inserm, CRO2 UMR&#95;S 911, Marseille, 13385, France.<br /><searchLink fieldCode="AU" term="%22Cvitkovic+E%22">Cvitkovic E</searchLink>; Oncology Therapeutic Development, 100 Rue Martre, Clichy, 92110, France.; Oncoethix SA (Now Oncoethix GmbH, a Wholly Owned Subsidiary of Merck Sharp and Dohme Corp.), Weystrasse 20, Lucerne, 6000, Switzerland.<br /><searchLink fieldCode="AU" term="%22Noel+K%22">Noel K</searchLink>; Oncoethix SA (Now Oncoethix GmbH, a Wholly Owned Subsidiary of Merck Sharp and Dohme Corp.), Weystrasse 20, Lucerne, 6000, Switzerland.<br /><searchLink fieldCode="AU" term="%22Bekradda+M%22">Bekradda M</searchLink>; Oncology Therapeutic Development, 100 Rue Martre, Clichy, 92110, France.<br /><searchLink fieldCode="AU" term="%22MacKenzie+S%22">MacKenzie S</searchLink>; Oncology Therapeutic Development, 100 Rue Martre, Clichy, 92110, France.<br /><searchLink fieldCode="AU" term="%22Rezai+K%22">Rezai K</searchLink>; Department of Radio-Pharmacology, Institut Curie, René Huguenin Hospital, 35 Rue Daily, Saint-Cloud, 92210, France.<br /><searchLink fieldCode="AU" term="%22Lokiec+F%22">Lokiec F</searchLink>; Department of Radio-Pharmacology, Institut Curie, René Huguenin Hospital, 35 Rue Daily, Saint-Cloud, 92210, France.<br /><searchLink fieldCode="AU" term="%22Riveiro+ME%22">Riveiro ME</searchLink>; Oncology Therapeutic Development, 100 Rue Martre, Clichy, 92110, France.<br /><searchLink fieldCode="AU" term="%22Ouafik+L%22">Ouafik L</searchLink>; Aix-Marseille Université, Inserm, CRO2 UMR&#95;S 911, Marseille, 13385, France. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%220042124%22">International journal of cancer</searchLink> [Int J Cancer] 2016 Nov 01; Vol. 139 (9), pp. 2047-55. <i>Date of Electronic Publication: </i>2016 Jul 30. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley-Liss%22">Wiley-Liss </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0042124 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1097-0215 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200207136%22">00207136 </searchLink><i>NLM ISO Abbreviation: </i>Int J Cancer <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=27388964 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1002/ijc.30256 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 2047 Titles: – TitleFull: OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Berenguer-Daizé C – PersonEntity: Name: NameFull: Astorgues-Xerri L – PersonEntity: Name: NameFull: Odore E – PersonEntity: Name: NameFull: Cayol M – PersonEntity: Name: NameFull: Cvitkovic E – PersonEntity: Name: NameFull: Noel K – PersonEntity: Name: NameFull: Bekradda M – PersonEntity: Name: NameFull: MacKenzie S – PersonEntity: Name: NameFull: Rezai K – PersonEntity: Name: NameFull: Lokiec F – PersonEntity: Name: NameFull: Riveiro ME – PersonEntity: Name: NameFull: Ouafik L IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 11 Text: 2016 Nov 01 Type: published Y: 2016 Identifiers: – Type: issn-electronic Value: 1097-0215 Numbering: – Type: volume Value: 139 – Type: issue Value: 9 Titles: – TitleFull: International journal of cancer Type: main |
| ResultId | 1 |
